NCT02452268 - A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 8, 2017

Primary Completion Date

March 7, 2022

Study Completion Date

March 7, 2022

Conditions

Metastatic and Advanced Solid Tumors

Interventions

DRUG

NIZ985

Subcutaneous administration of hetIL-15 three times a week for two consecutive weeks

DRUG

PDR001

• PDR001 is a human monoclonal antibody (MAb) administered day 1 of each cycle

Trial Locations (7)

National Cancer Institute National Cancer Institute, Bethesda

The Ohio State University Comprehensive Cancer Center, Columbus

University of Wisconsin, Madison

Washington University School of Medicine SC, St Louis

Huntsman Cancer Institute, Salt Lake City

Providence Portland Medical Center SC, Portland

Seattle Cancer Care Alliance, Seattle